After assessing the MEK and BRAF inhibitor resistance phenotypes of A375 melanoma model cell lines in both 2D and 3D tissue culture, we next evaluated each line for sensitivity to combination MEK/BRAF inhibitor treatment. This evidence concerns the gene MAP2K7 and melanoma.